0.02Open0.02Pre Close0 Volume597 Open Interest2.00Strike Price0.00Turnover154.61%IV27.85%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.1375Delta0.7047Gamma79.00Leverage Ratio-0.0057Theta0.0000Rho10.86Eff Leverage0.0004Vega
Regulus Therapeutics Stock Discussion
📊⚡️📊
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vanguard loaded
Regulus Therapeutics Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol RGLS, has recently announced positive topline results from the third cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) clinical trial of RGLS8429. This investigational drug is being developed for the treatment of ...
No comment yet